HC Wainwright restated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Tuesday morning,Benzinga reports. They currently have a $8.00 target price on the stock.
Separately, Ascendiant Capital Markets reduced their price target on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.
Plus Therapeutics Trading Down 1.6 %
Institutional Investors Weigh In On Plus Therapeutics
A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC purchased a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics at the end of the most recent reporting period. 3.28% of the stock is currently owned by institutional investors.
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Read More
- Five stocks we like better than Plus Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.